{"schema_version":"secwatch.filing_event.v1","accession":"0000937556-24-000062","form_type":"8-K","ticker":"MASI","cik":"0000937556","company_name":"MASIMO CORP","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.446241+00:00","generated_at":"2026-05-31T12:54:32.002995+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Masimo Q2 revenue $496.3M, GAAP EPS $0.29, non-GAAP $0.86; raises FY2024 guidance","bullets":["Healthcare revenue $343.9M, non-healthcare $152.4M; GAAP operating income $28.3M, non-GAAP $72.9M.","GAAP net income $16.0M ($0.29/diluted share); non-GAAP net income $46.6M ($0.86/diluted share).","Raises FY2024 guidance: consolidated revenue $2,085-$2,135M, healthcare $1,385-$1,405M.","FY2024 non-GAAP EPS guidance raised to $3.80-$4.00; Q3 revenue guidance $495-$515M.","CEO cites record-breaking contracting, margin expansion, and innovation for strong results."],"urls":{"canonical":"https://secwatch.observer/filing/0000937556-24-000062","json":"https://secwatch.observer/filing/0000937556-24-000062.json","markdown":"https://secwatch.observer/filing/0000937556-24-000062.md","text":"https://secwatch.observer/filing/0000937556-24-000062.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000062/0000937556-24-000062-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/937556/000093755624000062/masi-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:54:32.002995+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}